Global Vaccine Market At 10% Growth, Poised For Therapeutic Vaccines
This article was originally published in The Pink Sheet Daily
Robust growth is expected in the global vaccines market driven by new players and products, improved coverage and distribution in both developed and emerging markets, and higher prices for new vaccines, an IMS consultant said during a New York Pharma Forum presentation.
You may also be interested in...
Pfizer, which saw 13% growth in its global vaccines business during the second quarter, pays $635 million to buy a pair of vaccines from Baxter. The meningitis and encephalitis vaccines, sold mainly in Europe, are expected to generate combined sales of about $300 million this year.
Ex-Genentech executive Susan Desmond-Hellman soon will leave her position as UCSF chancellor to become CEO of the Gates Foundation. Her move signals the foundation’s ambition to lead in the science and the financing of neglected and tropical diseases, as well as in the global alliances that enable both.
Initiative to build health care infrastructure and create a sales channel for GSK medicines is starting to yield tangible results.